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Abstract
The quest for therapeutic applications of obestatin involves, as a first step, the determination of its 3D solution structure
and the relationship between this structure and the biological activity of obestatin. On this basis, we have employed
a combination of circular dichroism (CD), nuclear magnetic resonance (NMR) spectroscopy, and modeling techniques to
determine the solution structure of human obestatin (1). Other analogues, including human non-amidated obestatin (2) and
the fragment peptides (6–23)-obestatin (3), (11–23)-obestatin (4), and (16–23)-obestatin (5) have also been scrutinized.
These studies have been performed in a micellar environment to mimic the cell membrane (sodium dodecyl sulfate, SDS).
Furthermore, structural-activity relationship studies have been performed by assessing the in vitro proliferative capabilities
of these peptides in the human retinal pigmented epithelial cell line ARPE-19 (ERK1/2 and Akt phosphorylation, Ki67
expression, and cellular proliferation). Our findings emphasize the importance of both the primary structure (composition
and size) and particular segments of the obestatin molecule that posses significant a-helical characteristics. Additionally,
details of a species-specific role for obestatin have also been hypothesized by comparing human and mouse obestatins (1
and 6, respectively) at both the structural and bioactivity levels.
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Introduction
Obestatin, a 23-amino acid peptide derived from the ghrelin
peptide precursor (preproghrelin), was identified in 2005 as
a physiological opponent of ghrelin [1]. Obestatin was originally
isolated from the stomach and has subsequently been shown to be
a circulating peptide whose secretion is pulsatile. Obestatin
displays an ultradian rhythmicity similar to that of ghrelin and
GH secretion [2]. Moreover, obestatin was shown to bind
selectively to the orphan receptor GPR39, which belongs to the
same family as the ghrelin receptor GHS-R1a and the motilin
receptor [2], [3].
Although obestatin has been known as a controversial ghrelin-
associated peptide due to the lack of reproducible biological
actions on feeding, additional activities for this molecule have been
reported [4]. In particular, the proliferative abilities of obestatin
were first demonstrated in human retinal pigmented epithelial cells
[5], and the intracellular mechanisms responsible of this action
were later elucidated in human gastric cancer cell lines [6], [7],
thus defining the functionality to this biologically active peptide.
The ERK1/2 molecules control a large number of different or
even opposed cellular processes such as proliferation, survival,
development, stress response, and apoptosis [8]. Akt is a serine/
threonine kinase that acts as central player in the regulation of
several cell functions: protein synthesis, cell survival (one of the
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main factors in many cancer types) and metabolism (glucose
uptake, lipid homeostasis and protein synthesis) [9]. Deregulation
of these signals usually provokes diseases, such as cancer or
diabetes. Once obestatin activates GPR39, two routes are
triggered in parallel: i) sequential activation of Gi, PI3K, novel
PKCe and Src and the subsequent ERK1/2 activation; and ii) a b-
arrestin 1-mediated signaling pathway that involves the recruit-
ment of Src to the b-arrestin 1 scaffolding complex, thus causing
Akt phosphorylation. In this way, Src acts as a switch that activates
matrix metalloproteinases (MMPs) to initiate the proteolytic
release of the EGF-like ligands onto the cell surface, which later
bind to EGFR. The binding of the ligands leads to receptor
dimerization, which activates the intrinsic kinase and the specific
binding sites of phosphorylation, including PI3K. This kinase
activation allows for Akt phosphorylation in the A-loop (T308) and
the HM (S473) by PDK1 and mTORC2, respectively. The
activated Akt then inactivates the TSC1/TSC2 heterodimer to
activate mTORC1 and phosphorylate downstream targets, in-
cluding p70S6K1 [7]. The fact that obestatin modulates cell
proliferation, especially that of gastric cancer cells, suggests the
involvement of this peptide in diverse processes, such as the repair
of gastric mucosal damage or as a fuel for gastric cancer cell
proliferation. Subsequently, obestatin displayed a novel role as an
autocrine/paracrine regulator of adipogenesis and adipocyte
metabolism [10], [11]. All of the effects observed for obestatin
indicate that this molecule is a biologically relevant peptide and
not only a non-functional connective peptide.
Regarding the structure of obestatin, this peptide contains 23
amino acids with a post-translational amide modification on the
C-terminus. It is believed that this modification is essential for the
bioactivity of obestatin [1]. Recently, the relationship between the
primary structure and the bioactivity of mouse obestatin has been
studied, and it was concluded that the N-terminal 13 residues of
obestatin exhibit structural behavior most similar to that of the full
peptide [12]. Additionally, CD and NMR studies have been
performed to determine the possible secondary structure of mouse
obestatin (6) and its (11–23)-obestatin truncated isoform in the
presence of DPC/SDS micelles. The results showed that both
peptides assume regular secondary structures at the C-terminus
and that carboxy-amidation is a prerequisite for the biological
activity because it is necessary to induce and to stabilize the regular
conformations [13]. More recently, Subasinghage et al. have
performed a structure-bioactivity study using human obestatin.
These authors described the effects of human obestatin and its
(11–23)-obestatin isoform in rats [14]. In addition to these studies,
the availability of new data regarding the signaling mechanisms of
obestatin in human cell lines [5–7] has prompted us to develop
further studies on this topic. In this context, we have used CD,
NMR spectroscopy, and modeling techniques to determine the
solution structure of human obestatin (1), human non-amidated
obestatin (2) and the fragment peptides (6–23)-obestatin (3), (11–
23)-obestatin (4), and (16–23)-obestatin (5) in SDS micelles
(Figure 1). Furthermore, comparisons have been made between
the structural characteristics and the biological activities observed
for these peptides, as determined by their capabilities to stimulate
Akt and ERK1/2, the expression of the proliferation marker Ki67
and the cellular proliferative capabilities [15] in the human retinal
pigmented epithelial cell line ARPE-19. Additionally, the details of
the species-specific role of obestatin have also been deduced by
comparing human and mouse obestatin (1 and 6, respectively).
Materials and Methods
Materials
Human obestatin (1) and mouse obestatin (6) were obtained
from California Peptide Research Inc. (Napa, CA, US). Human
non-amidated obestatin and human (16–23)-obestatin were
purchased from Bachem Ltd. (St. Helens, UK). Human (6–23)-
obestatin was obtained from Biomedal (Sevilla, ES). Human (11–
23)-obestatin was obtained from Peptides International (Louisville,
KY, US).
The rabbit polyclonal IgG antibodies against phospho-p44/42
mitogen-activated protein kinase (MAPK), p44/42 MAPK,
phospho-Akt HM(S473), and Akt HM(S473) were purchased
from Cell Signaling Technology (Beverly, MA, US). The rabbit
polyclonal IgG antibodies against GPR39 and actin were obtained
from Abcam (Cambridge, UK). The anti-rabbit IgG horseradish
peroxidase was purchased from Jackson ImmunoResearch Europe
Ltd. (Suffolk, UK).
Cell culture
The retinal pigmented epithelium cell line ARPE-19 was
cultured as described by the supplier (ATCC, Manassas, VA,
US). Briefly, ARPE-19 cells were seeded in 100-mm dishes and
cultured in DMEM:F12 medium supplemented with 10% (v/v)
fetal bovine serum (FBS), 100 U/mL penicillin G, 100 mg/mL
streptomycin sulfate and 2.5 mM L-glutamine with 5% CO2 at
37uC.
Immunoblotting analysis
Serum-starved cells were stimulated with the peptides for the
indicated time period and doses at 37uC. The medium was then
aspirated, and the cells were lysed in ice-cold lysis buffer [RIPA
buffer: 50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1 mM EDTA,
1% (v/v) NP-40, 0.25% (w/v) Na-deoxycholate, protease inhibitor
cocktail (1:100, Sigma Chemical Co., St. Louis, MO, US),
phosphatase inhibitor cocktail (1:100, Sigma Chemical Co., St.
Louis, MO, US)]. The soluble cell lysates were pre-cleared by
centrifuging at 13,0006g for 15 min. The protein concentration
was evaluated using the QuantiProTM BCA Assay kit (Sigma
Figure 1. Primary structure of the obestatins used in this work: human obestatin (1), human non-amidated obestatin (2), human (6–
23)-obestatin (3), human (11–23)-obestatin (4), human (16–23)-obestatin (5) and mouse obestatin (6). The red-labeled residues in 6 are
different from those of 1.
doi:10.1371/journal.pone.0045434.g001
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Chemical Co., St. Louis, MO, US). The same amount of protein
for each sample was separated on 10% sodium dodecyl sulfate
(SDS)/polyacrylamide gels and transferred to nitrocellulose
membranes (Bio-Rad, Hercules, CA, US). The blots were
incubated with 5% non-fat milk in a Tris buffer solution
containing Tween-20 (TBST) [20 mM Tris-HCl (pH 8.0),
150 mM NaCl, 0.1% (v/v) Tween-20, used for all incubation
and washing steps] for 1 h. The blots were then incubated for 1 h
with the corresponding antibodies, according to the manufac-
turer’s instructions, and were subsequently incubated with the
peroxidase-conjugated IgG antibody. After washing, the signals
were visualized using an ECL plus Western Blotting Detection
System (GE-Amersham, Buckinghamshire, UK). The blots shown
are representative of three experiments. The image processing was
performed using the NIH Image Software ImageJ 1.38x.
Small Interfering RNA (siRNA) silencing of gene
expression
The following double-stranded siRNA duplexes of GPR39 were
used (Thermo Fisher Scientific, Dharmacon, Lafayette, CO, US;
ON-TARGETplus SMART pool L-005569-00-0005, Human
GPR39, NM_001508): 39-UCCAAUAUGUCCAUCUGUA-59,
39-GCGCGAAACCAGCCAAUUC-59, 39-GAGGCUGAUU-
GUUGUGACA-59, and 39-AACCAGAUUCGGAGGAUCA-59.
A non-silencing RNA duplex was used as a control for all siRNA
experiments. The ARPE cells were transfected using Lipofecta-
mine 2000 (Invitrogen; CA, US).
Immunocytochemistry detection of Ki67
The ARPE-19 cells were cultured at a density of 46103 cells per
well in the culture medium described above on 8-well Lab-Tek II
chamber slides covered with CC2 glass slide coverslips. After
2 days, the medium was renewed, and the cells were cultured in
a serum-free medium (300 mL) for 24 h. The cells were then
treated with FBS (10% v/v), human obestatin (1; 100 and
200 nM), human non-amidated obestatin (2; 100 and 200 nM)
and the fragment peptides (6–23)-obestatin (3; 100 and 200 nM),
(11–23)-obestatin (4; 100 and 200 nM), (16–23)-obestatin (5; 100
and 200 nM) and mouse obestatin (6; 100 and 200 nM) in fresh
DMEM:F12. After 24 h, the intact cells were fixed in 96% ethanol
for 1 h. The immunocytochemical technique was automatically
performed using an AutostainerLink 48 instrument (Dako,
Glostrup, DK). The FLEX primary antibody to Ki-67 (clone
MIB 1; Dako) was used. En Vision FLEX/HRP (Dako) was
employed as a detection system. Briefly, the procedure comprised
the following steps: 1) epitope retrieval in 10 mM citrate buffer
(pH 6.0) using a microwave (750 W, 10 min); 2) incubation with
peroxidase-blocking agent (5 min); 3) incubation with primary
antibody (30 min); 4) incubation with labeled polymer-horseradish
peroxidase (HRP, dextran polymer conjugated with HRP and
affinity-isolated goat anti-mouse immunoglobulins; 30 min); 5)
incubation with a diaminobenzidine (DAB) chromogen substrate
solution (10 min); and 6) counterstaining with Harris hematoxylin
(9 min). In all cases, triplicate dishes were used for each
experimental point.
Cell proliferation assay
The cell proliferation was measured using a BrdU cell
proliferation enzyme-linked immunosorbent assay (ELISA) kit
(Roche Diagnostics, Mannheim, DE). The BrdU assay was
performed according to the manufacturer’s protocol. ARPE-19
cells were cultured in a 96-well multiplate at a density of 26103
cells per well in the culture medium described above for 24 h. The
Figure 2. Secondary structure analyses performed using the DICHROWEB web server with the CONTINLL algorithm and reference
data set 4. The relative amounts of a-helix and b-sheet were determined by adding together the contributions from helix 1 plus helix 2 and strand 1
plus strand 2, respectively, whereas the amounts of b-turn and random structure were read directly from the output. The peptides clearly showed
greater helicity in SDS than in PBS.
doi:10.1371/journal.pone.0045434.g002
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procedure comprised the following steps: 1) 0% FBS for 24 h; 2)
stimulation with FBS (10% v/v), human obestatin (1, 100 nM),
human non-amidated obestatin (2, 100 nM) and the fragment
peptides (6–23)-obestatin (3, 100 nM), (11–23)-obestatin (4,
100 nM), (16–23)-obestatin (5, 100 nM) and mouse obestatin (6,
100 nM) in serum-deprived medium for 48 h; 3) incubation with
BrdU-labeling solution (10 mL, 3 h, 37uC); 4) removal of the
labeling solution and fixing with FixDenat solution (200 mL,
30 min, 25uC); 5) incubation with an anti-BrdU-peroxidase (POD)
antibody solution (100 mL, 90 min, 25uC); and 6) washing
followed by the addition of the substrate solution (100 mL,
30 min). The BrdU incorporation was quantified using the
spectrophotometric absorbance (370 nm) measured with a Reader
VersaMaxPLUS. The mean absorbance of the control cells
represented 100% cell proliferation, and the mean absorbance of
the treated cells was related to the control values to determine the
sensitivity. In all cases, each experimental point was replicated
eight times.
Immunocytochemistry detection of GPR39
The ARPE-19 cell samples were processed using standard
procedures [10]. The slides were consecutively incubated with 1)
anti-GPR39 rabbit polyclonal antibody (1:500) in Dako Chem-
Mate antibody diluent (Dako, Glostrup, DK); 2) EnVisionTM
peroxidase rabbit (Dako, Carpinteria, CA, US) as the detection
system; and 3) 3,39-diaminobenzidine-tetrahydrochloride (Dako
Figure 3. Plot of the chemical shifts indices (CSIs) for residues at the C-termini of the studied peptides. (A) CSIs of the backbone amide
protons (HN) and (B) CSIs of the alpha protons (Halpha). The peptide sequence (6) is aligned with that of the other peptides. The CSI is defined as dobs –
drandom-coil.
doi:10.1371/journal.pone.0045434.g003
Figure 4. Secondary helical structure based on the HN and Halpha chemical shifts indices determined using the RCI server. The
underlined residues were predicted to have secondary helical structure based on the HN and Halpha chemical shifts indices that were determined
using the RCI server (http://wishart.biology.ualberta.ca/rci). The residues within helical structures that extended over more than two residues are
represented in bold; these residues are located primarily at the C-terminus.
doi:10.1371/journal.pone.0045434.g004
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Liquid DAB + Substrate-chromogen system). The cell and tissue
sections were faintly counterstained with Harris hematoxylin.
NMR spectroscopy
Samples for the NMR experiments were prepared by dissolving
peptides in 500 mL of a d25-SDS aqueous solution (9:1 H2O:D2O,
PBS buffer at pH 6.5) to make a final concentration of
approximately 0.8–1.0 mM and a peptide/SDS ratio of approx-
imately 1/70. The NMR spectra were recorded at 298 K using
Bruker 600 and 700 MHz spectrometers equipped with a triple-
resonance Z gradient probe and processed using XWIN-NMR
software (Bruker Inc.; Billerica, MA, US). The resonance of
2,2,3,3-tetradeutero-3-trimethylsilylpropionic acid (TSP) was used
as a chemical shift reference in the 1H NMR experiments (d
TSP = 0 ppm). The one-dimensional (1D) 1H homonuclear
spectra were recorded in the Fourier mode using quadrature
detection. The two-dimensional (2D) 1H homonuclear TOCSY
(total correlation spectroscopy) and NOESY (nuclear Overhauser
effect spectroscopy) spectra were collected in the phase-sensitive
mode using time-proportional phase increments in t1. For each of
these experiments, 512 t1 increments were used. The free
induction decay in t2 consisted of 2048 data points over a spectral
width of 6009.615 Hz. In general, 409661024 data points were
collected for each block, and 96 transients were collected for the
2D experiments. The TOCSY spectra were recorded using the
MLEV-17 pulse sequence with mixing times (spin-lock) of 60–
80 ms. The NOESY experiments were acquired with mixing times
of 250–400 ms. The experimental data were acquired and
processed using the TopSpinTM (Bruker Inc; Billerica, MA, US)
program on a PC station. The data matrices were multiplied by
a qsine function in both dimensions and then zero-filled to 1024
data points in F1 prior to the Fourier transformation. The peptide
resonance assignments were obtained using standard strategies
based on the 2D NMR experiments.
Figure 5. Summary of sequential and medium-range NOE connectivities involving the NH, Ha and Hb protons of the peptides in
SDS micelles, as derived from CYANA calculation. The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A)
human obestatin (1), (B) human non-amidated obestatin (2), (C) human (6–23)-obestatin (3), (D) human (11–23)-obestatin (4), (E) human (16–23)-
obestatin (5) and (F) mouse obestatin (6). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the
differences between human obestatin (1) and mouse obestatin (6).
doi:10.1371/journal.pone.0045434.g005
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Structure calculation
The peak lists for the NOESY spectra recorded with a 0.25 s
mixing time were generated by interactive peak picking using the
CARA software [16]. The NOESY cross-peak volumes were
determined using the automated peak integration routine im-
plemented in CARA. Conversion of NOE peak intensities to
distance restraints was done using automatic calibration as
implemented in CYANA 2.1 [17]. The three-dimensional (3D)
structures of human obestatin (1) and its derivatives were
determined using the standard protocol of combined automated
NOE (nuclear Overhauser effect) assignment and the structure
calculation implemented in the CYANA 2.1 program. Seven
cycles of combined automated NOESY assignment and structure
calculations were followed by a final structure calculation. The
structure calculation started in each cycle from 100 randomized
conformers, and the standard simulated annealing schedule was
used. The 20 conformers with the lowest final CYANA target
function values were retained for analysis and passed to the next
cycle. Weak restraints on the phi/psi torsion-angle pairs and on
the side-chain torsion angles between tetrahedral carbon atoms
were applied temporarily during the high-temperature and cooling
phases of the simulated annealing schedule to favor the permitted
regions of the Ramachandran plot and the staggered rotamer
positions, respectively. The list of upper-distance bonds for the
final structural calculation consists of unambiguously assigned
upper-distance bonds and does not require the possible swapping
of diastereotopic pairs. The 20 conformers with the lowest final
CYANA target function values were subjected to restrained
energy-minimization in a water shell using the AMBER 8.0
program [18]. The resulting 20 energy-minimized CYANA
conformers represent the solution structures of human obestatin
(1) and its derivatives. The MOLMOL program was used to
visualize the 3D structures [19]. CYANA was used to obtain
statistics on the target function values, restraint violations and
Ramachandran plots according to the PROCHECK-NMR
conventions [20]. The RMSD (root mean square deviation) values
were calculated using CYANA for the superpositions of the
backbone N, Ca and C’ atoms and the heavy atoms throughout
the protein. To obtain the RMSD value of a structure represented
by a bundle of conformers, all of the conformers were super-
imposed on the average structure, and the average of the RMSD
values between the individual conformers and their average
coordinates was calculated.
CD spectroscopy
CD experiments of the peptides were performed using a 720-
Jasco spectropolarimeter (Tokyo, JP) and a 1-mm-path-length
quartz cuvette. The CD spectra of the peptides in the SDS
micellar solution were recorded using a H2O solution containing
40 mM peptide and SDS micelle at a concentration of 2.8 mM
(25uC). In all cases, 25 mM NaH2PO4/Na2HPO4 buffer was used
to maintain the pH at 6.5. The CD spectra presented are the
Table 1. Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin
(6).
Human obestatin
(1)
Human non
amidated-
obestatin (2)
Human
(6–23)-obestatin (3)
Human
(11–23)-obestatin (4)
Human
(16–23)-obestatin (5)
Mouse obestatin
(6)
Experimental restraints [a]
Sequential distances 267 145 145 184 123 284
Medium-range
distances (i–j) ,5
99 28 31 63 38 68
Long-range distances
(i–j) $5
2 0 0 0 2 7
Total 368 173 176 247 163 359
Final CYANA target
function value (A˚2) [b]
0.18 0.22 0.02 0.11 0.27 0.04
RMS deviations from ideal geometry [c]
Bond lengths (A˚) 0.005 0.005 0.004 0.004 0.004 0.005
Bond angles (u) 0.7 0.7 0.6 0.5 0.5 0.6
RMSD to mean
coordinates (A˚) [d]
(14–20) (14–20) (14–20) (14–20) (16–23) (14–20)
Backbone N, Ca, C’ 0.4260.21 1.4960.56 0.5560.23 0.0960.04 0.4960.24 0.4660.39
All heavy atoms 1.1960.38 2.6960.78 1.2460.27 0.4960.22 1.5060.40 0.9360.52
Ramachandran plot statistics [c]
Most favorable
regions (%)
71.4 72.3 69.6 70.5 60.0 77.4
Additional allowed
regions (%)
26.4 27.2 30.4 29.5 38.7 22.6
Generously allowed
regions (%)
0.0 0.1 0.0 0.0 1.3 0.0
Disallowed regions
(%)
2.2 0.3 0.0 0.0 0.0 0.0
[a] The final CYANA target function value was computed for the structures calculated using CYANA. [b] Average values of the 20 final energy-minimized CYANA
conformers. [c] Calculated using PROCHECK-NMR. [d] Atomic differences are given as the average RMS difference of the mean coordinate structure (mean).
doi:10.1371/journal.pone.0045434.t001
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average of 5 accumulations from 190 to 250 nm, which were
recorded with a bandwidth of 1 nm and a scanning speed of
20 nm/min. During all of the measurements, the trace of the high-
tension voltage remained less than 700 V, which should ensure the
reliability of the obtained data [21]. Baselines of either solvent or
micellar solutions without peptide were subtracted from each
respective sample to yield the contribution of the sample. The
secondary structure composition was estimated using the DI-
CHROWEB web server [22], [23] with the following algorithms:
CONTINLL, involving 2 different reference data sets, and K2d
[23].
Data analysis
All of the data are reported as the mean 6 SE. A statistical
ANOVA analysis was performed using an analysis of variance with
the Bonferroni post hoc test. Values of P,0.05 were considered to
be statistically significant and are marked with an asterisk (*).
Figure 6. Superimposition of the 20 best representative structures of peptides 1 to 6, as calculated from the NMR data for the
peptides in SDS micelles. (A) Human obestatin (1), (B) human non-amidated obestatin (2), (C) human (6–23)-obestatin (3), (D) human (11–23)-
obestatin (4), (E) human (16–23)-obestatin (5) and (F) mouse obestatin (6). The Tyr16 side chain is shown in blue.
doi:10.1371/journal.pone.0045434.g006
Figure 7. Comparison between the secondary helical structure based on the HN and Halpha chemical shifts indices determined using
the RCI server and the secondary helical structure obtained in our structures. The underlined residues were predicted to have secondary
helical structure based on the HN and Halpha chemical shifts indices obtained using the RCI server (http://wishart.biology.ualberta.ca/rci). The residues
within helical structures that extended over more than two residues are represented in bold; these residues are located primarily at the C-terminus.
The secondary helical structure obtained in our structures, as calculated by CYANA, included a-helix formation (green labels) and 310-helix formation
(blue labels).
doi:10.1371/journal.pone.0045434.g007
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Results and Discussion
1. Circular dichroism
Circular dichroism is a suitable and rapid approach to provide
information about the secondary structural features of peptides
such as obestatin in solution [24]. First, the influence of SDS
micelles on the secondary structure of the different peptides was
studied. A preliminary scanning of the conformational preferences
of the peptides was performed in 25 mM PBS and in an SDS
micelle solution. SDS was adopted based on the works of
Schwyzer, who hypothesized that previous contact with the
membrane is essential for the peptide to adopt the proper
conformation to further interact with its receptor [25].
As shown in Figure S1, the CD spectra of the peptides (40 mM)
suggested that random coil conformations were prevalent in PBS,
whereas the spectra recorded in the micelle solution indicated the
presence of a certain amount of a-helical structure (Figure S2).
Both human (1) and mouse obestatin (6) exhibited similar
tendencies (Figure S3).
The secondary structure analyses were performed using the
DICHROWEB web server [22], [23] with the following algo-
rithms: CONTINLL, which incorporated 2 different reference
data sets, and K2d [23]. The conformational weights of the
secondary structures obtained with CONTINLL were paired with
2 different data sets for the data ranging between 190 and 240 nm.
Although an important caveat of this method is that the reference
data sets are primarily appropriated for aqueous environments, it
is nonetheless evident that the peptides in SDS have the greatest
helicity (Table S1). An example of the obtained results is
represented in Figure 2.
2. Structure determination using nuclear magnetic
resonance (NMR)
The NMR spectra of the peptides were collected in the presence
of the SDS micelles. Peptides 1–6 provided well-dispersed 2D
spectra. A small number of cross-peaks were observed for peptides
2 and 3. Figure S4 and Figure S5 exemplify the quality of the
spectra, of which the amide region of the 2D NOESY spectra of
human obestatin (1) and its truncated analogue (4) are shown. The
assignment process was straightforward because most of the
proton resonances of these peptides at 298 K and pH 6.5 were
well resolved and narrow. The chemical shift assignment and
collection of the NOE data were performed by analyzing the 2D
TOCSY and NOESY spectra using the CARA software and
following standard procedures [16]. The proton chemical shifts of
the peptides in SDS micelles are summarized in the Supporting
Information: human obestatin (1), Table S2; human non-ami-
dated obestatin (2), Table S3; human (6–23)-obestatin (3),
Table S4; human (11–23)-obestatin (4), Table S5; human (16–
23)-obestatin (5), Table S6; and mouse obestatin (6), Table S7.
The experimental NMR data were used to generate 3D models of
peptides 1–6. The three-dimensional structures were calculated
using the CYANA software based on the inter-proton distance
restraints (sequential and medium-range NOE-derived restraints).
The best 20 structures, out of 50 calculated, were chosen according
to the lowest values of the penalty (f) for the target function. A
subsequent energy refinement was performed in explicit solvent
using the AMBER program. The corresponding results, including
the further analysis of the resulting structures performed using
MOLMOL and PROCHECK-NMR, are shown below.
2. 1. Backbone HN amide and H-alpha 1H chemical
shifts. First, the variation of the backbone amide HN and Halpha
chemical shift values was monitored for significant changes that
might have structural relevance. These chemical shifts in peptides
1–6 were, on average, shifted upfield in relation to the typical
values observed for random coils, as might be expected for helical
structures (Figure 3). Furthermore, the chemical shift analysis
performed using the RCI server [26] predicted helical conforma-
tions for the residues located mainly at the C-termini of the
peptides (Figure 4).
Figure 3 shows the chemical shift indices (CSI) for the HN and
Halpha protons of the residues at the C-termini of some of these
peptides. The CSIs for the HN and Halpha protons of human
obestatin (1) between residues Tyr16 and Leu23 are generally
(with a few exceptions) negative and much stronger than those of
the non-amidated obestatin (2), indicating that the latter has
a smaller percentage of helical structure at the C-terminus. The
CSIs for the HN and Halpha protons of human (6–23)-obestatin (3)
generally indicate a higher percentage of helical structure relative
to (1), suggesting that the lack of the first 5 amino acids does not
have an important conformational impact on the structure.
Figure 8. Analysis of the expression and functionality of GPR39
in ARPE-19 cells. (A) Immunocytochemical detection of GPR39 in
ARPE-19 cells (objective magnification of 20x). (B) The effect of siRNA
depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in ARPE-19
cells after human obestatin treatment (1, 100 nM, 10 min). The ARPE-19
cells were transfected with GPR39 siRNA prior to obestatin 1 treatment.
Equal amounts of protein in each sample were used to assess the
expression of GPR39 by western blotting. The GPR39 level was
expressed as the fold change relative to the control siRNA-transfected
cells (mean 6 SE). The protein expression was normalized relative to
actin. The data are expressed as the mean6 SE. The asterisk (*) denotes
P,0.05 when comparing the treated control siRNA group with the
control siRNA group; the dagger (#) denotes P,0.05 when comparing
the GPR39 siRNA group with the control siRNA group.
doi:10.1371/journal.pone.0045434.g008
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The truncated peptide 4, which lacks the first 10 residues, has
the strongest negative CSIs for both HN and Halpha protons, thus
providing further support for the formation of an a-helix at the C-
terminus of this peptide. In the case of mouse obestatin (6), the
negative CSIs for HN and Halpha are indicative of an a-helix,
although the comparison with the human obestatin (1) shows
considerable variations along the sequence without a clear trend.
2. 2. NOE pattern. Figure 5 contains a summary of all (short,
medium and long range) connectivities deduced from an analysis
of the NOESY spectra of the peptides. It has been previously
reported that poorly ordered structures of obestatin were observed
in water solutions. These peptides generally exhibited bend
structures in the central Lys10-Ala14 fragment [13], [14]. For
peptides 1–6 in buffered SDS micelles, the backbone and side-
chain proton NMR resonances could be completely assigned in
a sequential manner with the aid of the TOCSY and NOESY
spectra. A significant population of conformations containing an
‘‘ordered’’ a-helix is present, with characteristic short-range
dNN(i, i+1) and medium-range daN(i, i+3) and dab (i, i+3)
NOE connectivities [16]. Fairly strong dNN(i, i+1) and daN(i, i+1)
NOEs were observed for most of the residues, although some gaps
resulted from resonance overlap.
The data that were obtained clearly suggest the presence of
a significant population of ordered a-helical structures for these
peptides in SDS micelle solutions. In fact, for human obestatin (1),
clear medium- and long-range connectivities were observed
including 1) medium-range Hai/HNi+3 (Gly8/Leu11, Lys10/
Gly13, Leu11/Val14) and Hai/Hbi+3 (Val7/Lys10, Gly8/Leu11,
Gly13/Tyr16, Ser20/Leu23) connectivities and 2) a long-range
Hai/HNi+4 (Lys10/Val14) connectivity. For the non-amidated
peptide 2, fewer medium-range connectivities were observed
relative to the amidated peptide 1, including 1) medium-range
Hai/HNi+3 (Leu11/Val14, Gly13/Tyr16) connectivities but no
Hai/Hbi+3 connectivities and 2) a long-range Hai/HNi+4
(Lys10/Val14) connectivity. For the truncated human (6–23)-
obestatin (3), fewer medium-range connectivities were observed: 1)
medium-range Hai/HNi+3 (Gln17/Ser20, His19/Ala22) connec-
tivities but no Hai/Hbi+3 connectivities were observed, and 2) no
long-range Hai/HNi+4 connectivities were observed. The pres-
ence of medium-range connectivities (Hai/HNi+3, Hai/Hbi+3)
and long-range connectivities (Hai/HNi+4) from Gly13 to Leu23
confirmed the presence of a fairly well defined a-helical structure
at the C-terminus of human (11–23)-obestatin (4): 1) medium-
range Hai/HNi+3 (Gly13/Tyr16, Gln17/Ser20, Gln18/Gln21,
Ser20/Leu23) and Hai/Hbi+3 (Gly13/Tyr16, Gln15/Gln18,
Gln17/Ser20, Ser20/Leu23) connectivities were observed, and
2) long-range Hai/HNi+4 (Gly13/Gln17, Glu17/Gln21) connec-
tivities were observed. The observed structure of the human (16–
23)-obestatin (5) is not as well defined as that of 4. Only residues
His19/Leu23 are involved in a-helix formation: 1) medium-range
Hai/HNi+3 (His19/Ala22, Ser20/Leu23) connectivities and no
Hai/Hbi+3 connectivities were observed, and 2) a long-range
Hai/HNi+4 (His19/Leu23) connectivity was also observed. A
fairly similar pattern of NOEs, especially at the C-terminal region
Figure 9. Time-course of the effect of the different peptides on ERK1/2 [pERK 1/2 (T202/Y204)] and Akt [pAkt HM (S473)]
phosphorylation in ARPE-19 cells. The serum-starved cells were treated with the peptides (200 nM) at 37uC for the indicated times. The cells
were lysed and analyzed using SDS-PAGE with specific antibodies. ERK1/2 and Akt phosphorylation were quantified using densitometry and
expressed as the fold change relative to the phosphorylation obtained for unstimulated cells (mean 6 SE of five independent experiments).
doi:10.1371/journal.pone.0045434.g009
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of the peptide, was found in the SDS micelles compared with the
structure previously reported in DPC/SDS micelles [13] for
mouse obestatin (6): 1) medium-range Hai/HNi+3 (Ile9, Ser12,
Gln17/Gly20, Gly20/Leu23) and Hai/Hbi+3 Val7/Lys10,
Gly13/Tyr16) connectivities were observed, and 2) no long-range
Hai/HNi+4 connectivities, however, were observed (bold residues
are different from those of 1).
2. 3. 3D structures. The best 20 structures, which possessed
the lowest total energies, were considered as representatives of
human obestatin (1) and its analogues. None of these structures
had NOE violations greater than 0.2 A˚ or dihedral angle
violations greater than 2u. A summary of the structural character-
istics of the different peptide ensembles is given in Table 1. The
PROCHECK analysis of the 20 structures showed that almost all
of the residues are in the most favored and ‘additionally allowed’
regions of the Ramachandran plot. For instance, for 1, less than
3% of the residues were found outside the sterically allowed region
of the Ramachandran plot. This fact is mostly due to Ala3, which
is situated in the less-defined region of the structure (Table 1).
A view of the structures obtained for 1–6 superimposed along
their backbones is shown in Figure 6. These representations show
that these peptides primarily adopt an a-helical conformation at
the C-terminus (Figure 7).
The analysis of the bundle of 20 structures obtained for human
obestatin (1) demonstrated that in most of the structures, residues
Gly8-Leu11 were involved in an a-helix, whereas residues Val14-
Gln17 were involved in a 310 helix. In a few structures, residues
Ser20-Leu23 were further involved in an a-helix. This helical
pattern induced under our SDS micelles conditions appears to be
fairly similar to that previously reported in 33% TFE-water for the
Figure 10. Immunocytochemical analysis of the Ki67 expression and BrdU incorporation in ARPE-19 cells. Immunocytochemical
analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). C) 100 nM human obestatin (1). D) 100 nM
human non-amidated obestatin (2). E) 100 nM human (6–23)-obestatin (3). F) 100 nM human (11–23)-obestatin (4). G) 100 nM human (16–23)-
obestatin (5). H) 100 nM mouse obestatin (6). The magnification was 20x. I) Quantification of the immunocytochemical expression of Ki67 in ARPE-19
cells after treatment with 10% FBS (v/v; 10062), 100 nM human obestatin (1; 8461%), 100 nM human non-amidated obestatin (2; 3362%), 100 nM
human (6–23)-obestatin (3; 5663%), 100 nM human (11–23)-obestatin (4; 6763%), 100 nM human (16–23)-obestatin (5; 5062%) and 100 nM mouse
obestatin (6; 3262%). The expression of Ki67 was expressed as the fold change relative to the expression level in FBS-treated cells in the positive
control (mean6 SE). J) BrdU incorporation in ARPE-19 cells after treatment with 10% FBS (v/v; 10061), 100 nM human obestatin (1; 8464%), 100 nM
human non-amidated obestatin (2; 3962%), 100 nM human (6–23)-obestatin (3; 3061%), 100 nM human (11–23)-obestatin (4; 5263%), 100 nM
human (16–23)-obestatin (5; 3463%) and 100 nM mouse obestatin (6; 3561%). The BrdU incorporation was expressed as the fold change relative to
the level in FBS-treated cells in the positive control (mean 6 SE). The data are expressed as the mean 6 SE. The asterisk (*) denotes P,0.05 when
comparing the peptide-treated ARPE-19 cells groups with the human obestatin (1)-treated group.
doi:10.1371/journal.pone.0045434.g010
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same peptide [14]. Mean atomic RMSD values for the backbone
atoms (5–15) of 0.5260.25 A˚ and for the heavy atoms (5–15) of
1.0960.32 A˚ were calculated for the best 20 conformers of 1, and
these values are fairly similar to those reported by Subasinghage
under those experimental conditions [14]. For the human non-
amidated obestatin (2), the formation of a 310 helix between
residues Gly8-Ser12 and Val14-Gln17 was observed. Regarding
peptide 3, a 310 helix between residues Gly8-Ser12, Val14-Gln17
and His19-Gln21 was found. For the human (11–23)-obestatin (4),
the a-helix structure extended from Tyr16 to Leu23. The small
peptide 5 displays a short a-helix from Ser20 to Leu23. Finally,
our data suggest that the mouse obestatin (6) contained a 310 helix
between residues Gly8-Ser12 and Ala14-Gln17 and an a-helix
between His19-Ala22. The calculated 3D structures also corrob-
orate some details that were previously obtained from the
qualitative 1H chemical shift analysis described above. As can be
observed from these data, the amide moiety in 1 appears to be
important for stabilizing the a-helix conformation between
residues Ser20 and Leu23, and this moiety is absent in the non-
amidated peptide (Figure 6A and 6B).
3. Proliferation
3. 1. GPR39 siRNA depletion. GPR39 simultaneously
signals via two parallel pathways, using either heterotrimeric G
proteins or multifunctional adapters such as b-arrestin 1. Although
recent work has identified this receptor as a target for obestatin
action [10], [11], no data are available for the proposed cell model
of ARPE-19 cells, a human retinal pigment epithelial cell line.
Therefore, the endogenous expression of GPR39 was first
analyzed using immunocytochemistry (Figure 8A). Next, the effect
of acute GPR39 deficiency was determined using siRNA. Under
these conditions, the constructs exhibited a decrease in GPR39
expression by 5561% (Figure 8B). In the presence of a non-
targeting control siRNA, the phosphorylation of human obestatin-
activated Akt(S473) and ERK1/2(T202/Y204) were similar to
that observed without any transfection. The silencing of GPR39
subsequently decreased the levels of pAkt(S473) and pERK1/
2(T202/Y204) with respect to the siRNA control (to 9463% and
6065%, respectively) following treatment with human obestatin
(1, 100 nM) for 10 min (Figure 8B).
3. 2. ERK1/2 and Akt activation. We examined the
proliferative capabilities of the peptides by investigating ERK1/2
and Akt activation [pERK1/2(T202/Y204) and pAkt(S473)]. The
curves obtained after the treatment of ARPE-19 cells with the
peptides (100, 200 and 500 nM) exhibited a dose-dependent
pattern with a maximum at 200 nM (data not shown). This
maximum is the concentration reflected in Figure 9. The pattern
of ERK1/2 phosphorylation (Figure 9A) reached maximal levels
within 10 min of human obestatin stimulation (1, 200 nM) and
decreased to basal levels after 60 min. Conversely, the pAkt(S473)
maximal levels were reached after 10 min of stimulation with
human obestatin (1, 200 nM), and the activation was maintained
for at least 60 min (Figure 9B). In contrast, the human non-
amidated obestatin (2) did not influence pAkt(S473), and exhibit
even a slight inhibitory effect on pERK1/2(T202/Y204). From
these data, it can be deduced that amidation is a prerequisite for
maintaining the bioactivity of obestatin. Obestatins 3 and 5 had
no effect on either pAkt(S473) or pERK1/2(T202/Y204). In-
triguingly, the obestatin analogue 4 induced selective coupling to
the Akt signaling pathway and exhibited no effect on the ERK1/2
route over the time course of the assay. This particular ligand is
processed from full-length obestatin and is present in the stomach
[1]. In this sense, this peptide appears to selectively enhance
a restricted subset of active GPR39 conformations that are capable
of promoting specific aspects of the signaling pathway within the
GPR39-induced network, particularly b-arrestin-mediated signal-
ing mechanisms. This result suggests that this molecule may act as
a potential b-arrestin-biased agonist [27]. To date, biased ligands
have been identified for different G protein-coupled receptors,
denoting a new class of pharmacological ligands capable of
selective modulation [28].
Regarding the species-specific role of obestatin, the effect of
human (1) and mouse (6) obestatins on pERK1/2(T202/Y204)
and pAkt(S473) was compared under the same experimental
conditions described previously. Obestatin (6) treatment did not
induce any significant change in either pERK1/2(T202/Y204) or
pAkt(S473) during the tested period (Figure 9C and 9D). This
result demonstrates that, in this system, the changes in primary
(Val14Ala, Ser20Gly and Gln21Arg) and secondary structure
between species are critical for the activity. Thus, a species-specific
behavior occurs.
3. 3. Ki67 expression and proliferation. The activation of
the ERK1/2 and Akt signaling network results in the activation of
a series of transcription factors that induce alterations in the
expression of a variety of genes involved in the stimulation of cell
proliferation. Among these factors, Ki67 is a labile non-histone
nuclear protein that is intimately involved in the cell cycle [29].
The expression of Ki67 exhibits a good relationship with the
growing fraction in several system models, and this factor is not
expressed during the repair processes of DNA [30]. Thus, Ki67 is
considered to be a marker of cell proliferation.
Consequently, the mitogenic effect of the peptides was tested by
analyzing the expression of Ki67 in ARPE-19 cells using an
immunocytochemical analysis. The experiments were performed
at 24 h post-stimulation with the different peptides (100 nM).
Figure 10 shows a representative experiment of the six in-
dependent assays. Human obestatin (1) exhibited a clear increase
in immunostaining for Ki67 (Figure 10C), which was comparable
to the positive control [10% FBS (v/v); Figure 10B]. The negative
control (without stimuli) is shown in Figure 10A. In accordance
with the results from the immunoblots, the expression of Ki67 was
marginally detected for non-amidated obestatin (2) and mouse
obestatin (6) (Figure 10D and 10 H, respectively). Alternatively,
human (6–23)-obestatin (3) and human (16–23)-obestatin (5)
exhibited weak Ki67 expression (Figure 10E and 10G, re-
spectively), and the expression was higher for human (11–23)-
obestatin (4) (Figure 10F). These results (Figure 10I) resemble the
proliferative capabilities of human obestatin (1; 8464%) and the
different peptides measured in terms of BrdU incorporation, in
which only peptide 4 (5263%) exhibited a slight effect (Figure 10J).
Classically, agonists of the G protein-coupled receptor have
been thought to display a linear efficacy in which activation of the
receptor-related signaling network (e.g., G protein signaling,
receptor phosphorylation, b-arrestin recruitment and internaliza-
tion) is associated with the degree of the receptor activation, and
this activation ranges from partial to full. Nonetheless, it is now
recognized that b-arrestins initiate and determine the signals with
different spatial and temporal patterns, thus resulting in singular
cellular and pathophysiological consequences. This fact introduces
a new concept that proposes the efficacy of G protein-coupled
receptors as pluridimensional factors. This conclusion means that
G protein-coupled receptors exhibit different active conformations
that are able to trigger either the full range of receptor-associated
activities or a subset of these activities. In this context, it appears
that human obestatin (1) stabilizes the GPR39 conformations that
are necessary for the complete signaling associated with the G
protein and b-arrestin downstream pathways. This ligand action is
clearly determined by amidation at the C-terminus of human
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obestatin (1), which was shown to be essential for signaling in all
downstream pathways of the G protein- and b-arrestin-mediated
signaling with the subsequent activation of ERK1/2 and Akt,
respectively. As deduced from the structural studies, human non-
amidated obestatin (2) does not possess the a-helical pattern of 1,
such as the a-helix formed between Ser20 and Leu23 and the a-
helix formed from Gly8 to Lys11. Instead, a 310 helix appears
between Gly8 and Ser12. This structural change may be
responsible for the negligible effect of 2 on the expression of
Ki67, which is not comparable to that caused by human obestatin
(1). To date, Ki67 has not been unequivocally associated with
either the G protein- or b-arrestin-mediated signaling. In fact,
although Ki67 has been recognized as a relevant prognostic and
predictive marker for proliferation, the exact intracellular regula-
tion remains obscure. For 3, the absence of the first five residues
appears to be the key to the inability of this peptide to stabilize the
GPR39 conformations associated with the activation of the G
protein-dependent and b-arrestin-dependent signaling transduc-
tions. Furthermore, the impaired effect of peptide 3 on the
expression of Ki67 compared with that induced by 1 reinforces the
previous hypothesis. Regarding human (11–23)-obestatin (4), the
loss of the first ten residues leads to a significant change in
structure. This peptide presents the longer segment of an a-helix
spanning from Tyr16 to Leu23. The biological data show that this
ligand induces a selective coupling to only the b-arrestin portion of
the GPR39 downstream signaling pathways. This evidence
suggests that this peptide stabilizes a receptor conformation
distinct from that induced by 1. Interestingly, 4 exhibited a higher
level of Ki67 expression than the other truncated obestatin
analogues did. It is tempting to speculate that the structure of this
ligand represents a key element needed for the stabilization of the
GPR39 conformation coupled to b-arrestin signaling, thus
controlling its interaction patterns and related functions. Finally,
human (16–23)-obestatin (5) possesses a helical structure at its C-
terminus. Nevertheless, its small size does not seem to be able to
modulate the full range of GPR39 activities. Altogether, these
results support the notion that more than one active conformation
of GPR39 indeed exists and that the different ligands are able to
stabilize a different subset of the available receptor conformations.
The behavior of mouse obestatin (6) is also unique. This peptide
is the same size as 1 and is also subject to amidation at its C-
terminus. Moreover, 6 displays a characteristic pattern of helix
sets: Gly8-Ser12, Ala14-Gln17, and His19-Ala22. Indeed, the first
two helical regions are coincident with the 310-helix fragment
present in 3. However, the presence of this type of helix in 6 does
not result in the activation of the human GPR39 receptor in
ARPE-19 cells. In fact, mouse obestatin (6) did not activate either
G protein-dependent or b-arrestin-dependent signal transduction
over the time period studied. Additionally, this peptide failed to
induce Ki67 expression, which is similar to the behavior of human
non-amidated obestatin (2). An inspection of the primary sequence
indicated that the differences in primary structure between 1 and 6
are limited to only three amino acid residues, namely Val14Ala,
Ser20Gly and Gln21Arg. The major dissimilarity is observed for
Arg21, which can be positively charged. Spatially, this residue is
located only two residues away from the neighboring amidated
Leu23. Thus, these structural differences may be responsible for
the different bioactivities observed. Thus, in our biological model
system, the activity of obestatin is species-specific.
Conclusions
A structure-activity relationship for obestatin has been derived by
employing this peptide and several analogues as ligands for the
seven-transmembrane receptor GPR39. The analysis of the data
suggests that amidation at the C-terminus of human obestatin (1) is
essential for this molecule to adopt an a-helix structure. This a-helix
exists between Ser20 and Leu23 and from Gly8 to Lys11. The
presence of this structure correlates with the stabilization of the
GPR39 conformations that are necessary for the full range of
receptor activities, e.g., G protein-dependent and b-arrestin-de-
pendent signaling. Indeed, the change of this a-helix to a 310 helix or
the loss of this a-helical pattern can be correlated with the absence of
complete activation, as observed for non-amidated obestatin (2).
Additionally, GPR39 is able to adopt multiple active conformations,
which are related to the activation of specific signaling mechanisms.
In particular, human (11–23)-obestatin (4) is able to induce selective
coupling to a portion of the downstream signaling pathways, e.g., b-
arrestin-dependent signaling. This observation supports the idea
that 4 stabilizes a receptor conformation different from that induced
by human obestatin (1). Most likely, this activity is related to the
presence of the a-helix segment from Tyr16 to Leu23. Because this
peptide is present in the stomach, it might represent the first example
of an endogenous biased ligand for GPR39. Finally, mouse (6) and
human obestatin (1) exhibit clear conformational differences beyond
their differences in primary structure. The mouse analogue adopts
a distinct three-dimensional structure, which cannot activate human
GPR39. This evidence supports the existence of a species-specific
activity. Overall, the data presented herein provide a new structural
background, which could be useful for the development of particular
ligands that are able to discernibly improve, diminish or inhibit
specific aspects of the GPR39-associated signaling pathways.
Supporting Information
Figure S1 Far-UV CD spectra of the peptides in 25 mM
PBS under identical conditions. The concentration was
40 mM in all samples. Color code: solid blue, human obestatin (1);
dotted blue, non-amidated obestatin (2); solid red, human (6–23)-
obestatin (3); dotted red, (11–23)-obestatin (4); and solid green,
(16–23)-obestatin (5).
(TIF)
Figure S2 Far-UV CD spectra of the peptides in 2.8 mM
SDS under identical conditions. The concentration was
40 mM in all samples. Color code: solid blue, human obestatin (1);
dotted blue, non-amidated obestatin (2); solid red, human (6–23)-
obestatin (3); dotted red, (11–23)-obestatin (4); and solid green,
(16–23)-obestatin (5).
(TIF)
Figure S3 Far-UV CD spectra of human obestatin (1)
and mouse obestatin (6) in 25 mM PBS or 2.8 mM SDS
under identical conditions. The concentration was 40 mM in
all samples. Colour code: solid red, human obestatin (1) in SDS;
dotted red, human obestatin (1) in PBS; solid blue, mouse
obestatin (6) in SDS; and dotted blue, mouse obestatin (6) in PBS.
(TIF)
Figure S4 Amide region of 2D NOESY spectra for
human obestatin (1) in SDS micelles.
(TIF)
Figure S5 Amide region of 2D NOESY spectra for
human (11–23)-obestatin (4) in SDS micelles.
(TIF)
Table S1 Quantification of obestatins secondary struc-
ture by CD. The following table describes the quantification of
the CD spectra in two different environments. The quantification
was performed using the DICHROWEB server and the data were
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fit using K2d and CONTINLL. The latter was paired with two
different data sets for data ranging from 190 to 240 nm. The
NRMSD refers to the quality of the curve fitting based on the
reference data sets.
(TIF)
Table S2 1H chemical shifts (p.p.m.) for human obes-
tatin (1) in SDS-d25 micelles at 298 K.
(TIF)
Table S3 1H chemical shifts (p.p.m.) for human non-
amidated obestatin (2) in SDS-d25 micelles at 298 K.
(TIF)
Table S4 1H chemical shifts (p.p.m.) for human (6–23)-
obestatin (3) in SDS-d25 micelles at 298 K.
(TIF)
Table S5 1H chemical shifts (p.p.m.) for human (11–23)-
obestatin (4) in SDS-d25 micelles at 298 K.
(TIF)
Table S6 1H chemical shifts (p.p.m.) for human (16–23)-
obestatin (5) in SDS-d25 micelles at 298 K.
(TIF)
Table S7 1H chemical shifts (p.p.m.) for mouse obesta-
tin (6) in SDS-d25 micelles at 298 K.
(TIF)
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